About

Kangstem Biotech Co., Ltd. (Kangstem) is dedicated to develop stem cell therapy products that can address unmet medical needs. Kangstem’s mission is to give hope for the patients with rare and incurable diseases. Kangstem is located in South Korea and was listed on KOSDAQ in 2015 Kangstem developed super-gap technology strategy in stem cells, SELAF. SELAF is a proprietary platform with a one-stop optimized platform that covers the entire process from the selection and mass production for maximizing the efficacy of the stem cells to the production of finished products using state-of-the-art freezing technology. With its advanced technology, Kangstem aspires to be a leader in stem cell and regenerative medicine. Major pipelines are Atopic Dermatitis (Furestem-AD®; Phase 3), Osteoarthritis (Furestem-OA Kit Inj.; Phase1/2a), Rheumatoid Arthritis (Furestem-RA®; Phase2b), and Organoid (Skin, Pancreatic Islets) About Kangstem Biotech Co., Ltd. Kangstem Biotech(KSB) is a stem cell R&D company aiming to develop treatment for osteoarthritis and atopic dermatitis. KSB is also developing organoids, also known as organ analogs or mini-organs. Osteoarthritis program (OSCA): Completed Phase 1 and confirmed cartilage regeneration, pain relief and anti-inflammation. Phase 2 is currently ongoing. Atopic dermatitis program (Furestem-AD): Single dose Phase 3 is completed and KSB is preparing for multi dose Phase 2 study. Organoids: - Hair Follicle organoid - Skin Organoid (normal organoid and disease modeling organoid) - Islet organoid